For example, Inotuzumab ozogamicin is an anti-CD22 antibody drug conjugate that is set to deliver cytotoxic drugs to B-ALL cells expressing CD22, and shown great outcomes in patients with relapsed or refractory ALL (Kantarjian et al., 2016). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.